Dasatinib is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. It inhibits BCR-ABL and SRC family kinases. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sprycel and Dasatinib anhydrous. Its PubChem CID is 3062316.
Dasatinib
| CAS No | 302962-49-8 |
|---|---|
| Molecular Formula | C22H26ClN7O2S |
| Molecular Weight | 488.0 g/mol |
| Synonyms | N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Dasatinib is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. It inhibits BCR-ABL and SRC family kinases.
The listed CAS number is 302962-49-8.
The listed molecular formula is C22H26ClN7O2S.
The listed molecular weight is 488.0 g/mol.
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide.
The source lists Sprycel and Dasatinib anhydrous.